RESUMO
OBJECTIVE: Understanding cardiorenal pathophysiology in heart failure (HF) is of clinical importance. We sought to characterize the renal hemodynamic function and the transrenal gradient of the renin-angiotensin-aldosterone system (RAAS) markers in patients with HF and in controls without HF. METHODS: In this post hoc analysis, the glomerular filtration rate (GFRinulin), effective renal plasma flow (ERPFPAH) and transrenal gradients (arterial-renal vein) of angiotensin converting enzyme (ACE), aldosterone, and plasma renin activity (PRA) were measured in 47 patients with HF and in 24 controls. Gomez equations were used to derive afferent (RA) and efferent (RE) arteriolar resistances. Transrenal RAAS gradients were also collected in patients treated with intravenous dobutamine (HF, nâ¯=â¯11; non-HF, nâ¯=â¯11) or nitroprusside (HF, nâ¯=â¯18; non-HF, nâ¯=â¯5). RESULTS: The concentrations of PRA, aldosterone and ACE were higher in the renal vein vs the artery in patients with HF vs patients without HF (P < 0.01). In patients with HF, a greater ACE gradient was associated with greater renal vascular resistance (râ¯=â¯0.42; P 0.007) and greater arteriolar resistances (RA: râ¯=â¯0.39; Pâ¯=â¯0.012; RE: râ¯=â¯0.48; Pâ¯=â¯0.002). Similarly, a greater aldosterone gradient was associated with lower GFR (râ¯=â¯-0.51; Pâ¯=â¯0.0007) and renal blood flow (RBF), râ¯=â¯-0.32; Pâ¯=â¯0.042) whereas greater PRA gradient with lower ERPF (râ¯=â¯-0.33; Pâ¯=â¯0.040), GFR (râ¯=â¯-0.36; Pâ¯=â¯0.024), and RBF (râ¯=â¯-0.33; Pâ¯=â¯0.036). Dobutamine and nitroprusside treatment decreased the transrenal gradient of ACE (Pâ¯=â¯0.012, P < 0.0001, respectively), aldosterone (Pâ¯=â¯0.005, Pâ¯=â¯0.030) and PRA (Pâ¯=â¯0.014, Pâ¯=â¯0.002) in patients with HF only. CONCLUSIONS: A larger transrenal RAAS marker gradient in patients with HF suggests a renal origin for neurohormonal activation associated with a vasoconstrictive renal profile.
Assuntos
Insuficiência Cardíaca , Sistema Renina-Angiotensina , Aldosterona/uso terapêutico , Biomarcadores , Dobutamina/uso terapêutico , Insuficiência Cardíaca/diagnóstico , Insuficiência Cardíaca/tratamento farmacológico , Hemodinâmica , Humanos , Nitroprussiato/uso terapêutico , Renina/uso terapêuticoRESUMO
Kidney transplantation is the therapy of choice for patients with end-stage renal disease. Preexisting diabetes is highly prevalent in kidney transplant recipients (KTR), and the development of posttransplant diabetes is common because of a number of transplant-specific risk factors such as the use of diabetogenic immunosuppressive medications and posttransplant weight gain. The presence of pretransplant and posttransplant diabetes in KTR significantly and variably affect the risk of graft failure, cardiovascular disease (CVD), and death. Among the many available therapies for diabetes, there are little data to determine the glucose-lowering agent(s) of choice in KTR. Furthermore, despite the high burden of graft loss and CVD among KTR with diabetes, evidence for strategies offering cardiovascular and kidney protection is lacking. Recent accumulating evidence convincingly shows glucose-independent cardiorenal protective effects in non-KTR with glucose-lowering agents, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Therefore, our aim was to review cardiorenal protective strategies, including the evidence, mechanisms, and rationale for the use of these glucose-lowering agents in KTR with diabetes.
Assuntos
Doenças Cardiovasculares , Diabetes Mellitus Tipo 2 , Transplante de Rim , Doenças Cardiovasculares/prevenção & controle , Diabetes Mellitus Tipo 2/etiologia , Diabetes Mellitus Tipo 2/prevenção & controle , Humanos , Transplante de Rim/efeitos adversos , Inibidores do Transportador 2 de Sódio-Glicose/uso terapêutico , TransplantadosRESUMO
Pharmacological Na+-glucose linked cotransporter (SGLT)2 inhibition is being examined as a renal protection strategy in nondiabetic chronic kidney disease. We quantified renal SGLT mRNA expression in healthy controls (HC), glomerulonephritis (GN), and diabetic kidney disease (DKD) to identify differences in expression across a spectrum of renal diseases. mRNA expression of SGLT1 and SGLT2 in renal tubules and glomeruli, obtained using microdissection and microarray techniques, was evaluated in two large cohorts. The European Renal cDNA bank included HC, GN, and DKD (98 glomeruli and 93 tubulointerstitium). The Nephrotic Syndrome Study Network cohort included 124 adults with membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis, and IgA nephropathy. Within the European Renal cDNA bank, SGLT2 tubular and glomerular log2 mRNA expression significantly differed across HC, GN, and DKD (P = 0.0009 and P = 0.0004), with the highest expression in HC. Within the Nephrotic Syndrome Study Network, there were no differences in SGLT log2 mRNA expression across GN subtypes. Tubular SGLT2 log2 mRNA expression positively correlated with estimated glomerular filtration rate (by the Modification of Diet in Renal Disease Study equation) and glycated hemoglobin (r = 0.33 and 0.34, P < 0.05) and inversely correlated with interstitial fibrosis (r = -0.21, P < 0.05). In conclusion, SGLT2 mRNA expression was lower in DKD compared with HC or GN and inversely related to interstitial fibrosis. The relationships between SGLT mRNA, protein expression, and transporter activity require further elucidation.